With “Orphan Drug Designation” status, SPEDOX-6’s current human phase Ib/IIa clinical trials for treating STS underway will provide more information on establishing the correlation between antitumor efficacy of SPEDOX-6 and FcRn expression levels of cancer tissues. Here, FCGRT is linked to telomere syndrome.